Treatment and outcome of aquaporin-4 antibody-positive NMOSD: A multinational pediatric study.
Renata Barbosa PaoliloYael HacohenElise YazbeckThais ArmangueArlette BruijstensChristian LechnerSamira Luisa Apostolos-PereiraYana MartynenkoMarkus BreuCarolina de Medeiros RimkusEvangeline WassmerMatthias BaumannLaura PapettiMarco CapobiancoBarbara KornekKevin RostásyJosé Albino da PazOlga CiccarelliMing LimAlbert SaizRinze Frederik NeuteboomRomain MarignierCheryl HemingwayDouglas Kazutoshi SatoKumaran DeivaPublished in: Neurology(R) neuroimmunology & neuroinflammation (2020)
This study provides Class IV evidence that for children with AQP4-Ab NMOSD, all DMTs, particularly first-line rituximab, reduced the ARR and prevented further clinical relapses.